HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical trials of targeted toxins.

Abstract
Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.
AuthorsA E Frankel, E P Tagge, M C Willingham
JournalSeminars in cancer biology (Semin Cancer Biol) Vol. 6 Issue 5 Pg. 307-17 (Oct 1995) ISSN: 1044-579X [Print] England
PMID8562908 (Publication Type: Journal Article, Review)
Chemical References
  • Bacterial Toxins
  • Diphtheria Toxin
  • Exotoxins
  • Immunotoxins
  • Recombinant Fusion Proteins
  • Virulence Factors
  • Ricin
  • ADP Ribose Transferases
  • Pseudomonas aeruginosa exotoxin A
Topics
  • ADP Ribose Transferases
  • Bacterial Toxins
  • Clinical Trials as Topic
  • Diphtheria Toxin (therapeutic use)
  • Exotoxins (therapeutic use)
  • Humans
  • Immunotoxins (therapeutic use)
  • Neoplasms (therapy)
  • Recombinant Fusion Proteins (therapeutic use)
  • Ricin (therapeutic use)
  • Virulence Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: